Current status of extracorporeal life support (ECMO) for cardiopulmonary failure

R. H. Bartlett, L. Gattinoni

Research output: Contribution to journalArticle

Abstract

Extracorporeal life support with artificial heart and lung for cardiopulmonary failure is commonly called extracorporeal membrane oxygenation (ECMO). ECMO can provide partial or total support, is temporary, and requires systemic anticoagulation. ECMO controls gas exchange and perfusion, stabilizes the patient physiologically, decreases the risk of ongoing iatrogenic injury, and allows ample time for diagnosis, treatment, and recovery from the primary injury or disease. ECMO is used in a variety of clinical circumstances and the results depend on the primary indication. ECMO provides life support but is not a form of treatment. Survival ranges from 30% in extracorporeal cardiopulmonary resuscitation to 95% for neonatal meconium aspiration syndrome. The major limitations to widespread applications are the need for anticoagulation and bleeding complications. However, nowadays, the new devices allow only minor bleeding that is rarely a fatal complication. Research on non-thrombogenic surfaces holds the promise of prolonged extracorporeal circulation without anticoagulation and without bleeding. The next decade may bring routine application of ECMO to all advanced Intensive Care Units where patients with profound respiratory and cardiac failure are treated.

Original languageEnglish
Pages (from-to)534-540
Number of pages7
JournalMinerva Anestesiologica
Volume76
Issue number7
Publication statusPublished - Jul 2010

Fingerprint

Extracorporeal Membrane Oxygenation
Hemorrhage
Meconium Aspiration Syndrome
Artificial Heart
Extracorporeal Circulation
Cardiopulmonary Resuscitation
Wounds and Injuries
Respiratory Insufficiency
Intensive Care Units
Heart Failure
Perfusion
Gases
Equipment and Supplies
Lung
Survival
Therapeutics
Research

Keywords

  • Extracorporeal membrane oxygenation
  • Heart arrest
  • Life support systems

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. / Bartlett, R. H.; Gattinoni, L.

In: Minerva Anestesiologica, Vol. 76, No. 7, 07.2010, p. 534-540.

Research output: Contribution to journalArticle

Bartlett, R. H. ; Gattinoni, L. / Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. In: Minerva Anestesiologica. 2010 ; Vol. 76, No. 7. pp. 534-540.
@article{3618e0ee312e46d894d8542462c75c52,
title = "Current status of extracorporeal life support (ECMO) for cardiopulmonary failure",
abstract = "Extracorporeal life support with artificial heart and lung for cardiopulmonary failure is commonly called extracorporeal membrane oxygenation (ECMO). ECMO can provide partial or total support, is temporary, and requires systemic anticoagulation. ECMO controls gas exchange and perfusion, stabilizes the patient physiologically, decreases the risk of ongoing iatrogenic injury, and allows ample time for diagnosis, treatment, and recovery from the primary injury or disease. ECMO is used in a variety of clinical circumstances and the results depend on the primary indication. ECMO provides life support but is not a form of treatment. Survival ranges from 30{\%} in extracorporeal cardiopulmonary resuscitation to 95{\%} for neonatal meconium aspiration syndrome. The major limitations to widespread applications are the need for anticoagulation and bleeding complications. However, nowadays, the new devices allow only minor bleeding that is rarely a fatal complication. Research on non-thrombogenic surfaces holds the promise of prolonged extracorporeal circulation without anticoagulation and without bleeding. The next decade may bring routine application of ECMO to all advanced Intensive Care Units where patients with profound respiratory and cardiac failure are treated.",
keywords = "Extracorporeal membrane oxygenation, Heart arrest, Life support systems",
author = "Bartlett, {R. H.} and L. Gattinoni",
year = "2010",
month = "7",
language = "English",
volume = "76",
pages = "534--540",
journal = "Minerva Anestesiologica",
issn = "0375-9393",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "7",

}

TY - JOUR

T1 - Current status of extracorporeal life support (ECMO) for cardiopulmonary failure

AU - Bartlett, R. H.

AU - Gattinoni, L.

PY - 2010/7

Y1 - 2010/7

N2 - Extracorporeal life support with artificial heart and lung for cardiopulmonary failure is commonly called extracorporeal membrane oxygenation (ECMO). ECMO can provide partial or total support, is temporary, and requires systemic anticoagulation. ECMO controls gas exchange and perfusion, stabilizes the patient physiologically, decreases the risk of ongoing iatrogenic injury, and allows ample time for diagnosis, treatment, and recovery from the primary injury or disease. ECMO is used in a variety of clinical circumstances and the results depend on the primary indication. ECMO provides life support but is not a form of treatment. Survival ranges from 30% in extracorporeal cardiopulmonary resuscitation to 95% for neonatal meconium aspiration syndrome. The major limitations to widespread applications are the need for anticoagulation and bleeding complications. However, nowadays, the new devices allow only minor bleeding that is rarely a fatal complication. Research on non-thrombogenic surfaces holds the promise of prolonged extracorporeal circulation without anticoagulation and without bleeding. The next decade may bring routine application of ECMO to all advanced Intensive Care Units where patients with profound respiratory and cardiac failure are treated.

AB - Extracorporeal life support with artificial heart and lung for cardiopulmonary failure is commonly called extracorporeal membrane oxygenation (ECMO). ECMO can provide partial or total support, is temporary, and requires systemic anticoagulation. ECMO controls gas exchange and perfusion, stabilizes the patient physiologically, decreases the risk of ongoing iatrogenic injury, and allows ample time for diagnosis, treatment, and recovery from the primary injury or disease. ECMO is used in a variety of clinical circumstances and the results depend on the primary indication. ECMO provides life support but is not a form of treatment. Survival ranges from 30% in extracorporeal cardiopulmonary resuscitation to 95% for neonatal meconium aspiration syndrome. The major limitations to widespread applications are the need for anticoagulation and bleeding complications. However, nowadays, the new devices allow only minor bleeding that is rarely a fatal complication. Research on non-thrombogenic surfaces holds the promise of prolonged extracorporeal circulation without anticoagulation and without bleeding. The next decade may bring routine application of ECMO to all advanced Intensive Care Units where patients with profound respiratory and cardiac failure are treated.

KW - Extracorporeal membrane oxygenation

KW - Heart arrest

KW - Life support systems

UR - http://www.scopus.com/inward/record.url?scp=77955001122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955001122&partnerID=8YFLogxK

M3 - Article

C2 - 20613694

AN - SCOPUS:77955001122

VL - 76

SP - 534

EP - 540

JO - Minerva Anestesiologica

JF - Minerva Anestesiologica

SN - 0375-9393

IS - 7

ER -